Travere Therapeutics, Inc. (TVTX): R&D Expense
$206.01M
Year ended 2025-12-31
$227.14M
Trailing 12 months to 2026-06-30
-3.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $206.01M | -5.3% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $217.50M | -11.2% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $244.99M | +7.8% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $227.33M | +13.0% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $201.16M | n/c | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $131.77M | -6.5% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $140.96M | +13.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $123.76M | +58.3% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $78.17M | +10.4% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $70.82M | +40.4% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $50.43M | +5.5% | 2018-07-06, From 2015-01-01 |
| 2014-12-31 | $47.80M | +574.7% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $7.08M | +969.3% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $662.5K | n/a | 2015-07-09, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.54M | -11.4% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $30.60M | +124.1% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $71.53M | +36.7% |
Compare TVTX, NATR, BBIO, MIRM side by side · Screen every company in Pharmaceutical Preparations ↗